1

HIV and AIDS Articles by Topic - A to Z  

 Google Custom Search

European AIDS Clinical Society Issues New Guidelines for Treatment of HIV, HIV and Hepatitis Coinfection, and Management of Metabolic Complications

By Ronald Baker, PhD and Liz Higleyman

The European AIDS Clinical Society (EACS) has released new, revised guidelines for the treatment of HIV monoinfection in adults and HIV coinfection with hepatitis B and hepatitis C.

Last updated in 2003, the new recommendations were presented October 26, 2007 at the 11th annual EACS conference in Madrid, Spain (October 24-27, 2007).

Overall, the new guidelines reflect a more aggressive approach to initiation of treatment for HIV monoinfection, management of HIV-related metabolic complications, and treatment of HIV-HCV and HIV-HBV coinfection.

The guidelines state that HIV viral load suppression below 50 copies/mL should be the goal of antiretroviral therapy for both treatment-experienced and treatment-naive individuals. Treatment is recommended for patients with fewer than 350 cells/mm3, bringing the European guidelines more in accord with U.S. HIV treatment guidelines.

In this issue, HIV and Hepatitis.com presents summaries of the highlights of the 3 new EACS documents:


The full text of the 3
documents is available
in PDF format:
Guidelines for the Clinical Management and Treatment of HIV-infected Adults in Europe
Guidelines on the Prevention and Management of Metabolic Diseases in HIV
Guidelines for the Clinical Management and Treatment of Chronic Hepatitis B and C co-infection in HIV-infected Adults

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FDA-Approved
Treatments
Protease Inhibitors
Agenerase
Agenerase (amprenavir)
Aptivus
Aptivus (tipranavir)
Crixivan
Crixivan (indinavir)
Invirase
Invirase (saquinavir hard gel)
Kaletra
Kaletra (lopinavir/ritonavir)
Lexiva
Lexiva (fosamprenavir)
Norvir
Norvir (ritonavir)
Prezista
Prezista (darunavir)
Reyataz
Reyataz (atazanavir)
Viracept
Viracept (nelfinavir)
Nucleoside / Nucleotide Reverse Transcriptase Inhibitors
CombivirCombivir (zidovudine/lamivudine)
EpivirEpivir (lamivudine; 3TC)
EmtrivaEmtriva (emtricitabine; FTC)
EpzicomEpzicom (abacavir + lamivudine)
RetrovirRetrovir (zidovudine; AZT)
TrizivirTrizivir (abacavir + zidovudine +lamivudine)
TruvadaTruvada  (tenofovir / emtricitabine)
VidexVidex (didanosine; ddI)
VireadViread (tenofovir)
ZeritZerit (stavudine; d4T)
ZiagenZiagen (abacavir)
non Nucleoside Reverse
Transcriptase Inhibitors
RescriptorRescriptor (delavirdine)
SustivaSustiva (efavirenz)
ViramuneViramune (nevirapine)
Entry Inhibitors
(including Fusion Inhibitors)
Fuzeon (enfuvirtide, T-20)
Selzentry ( maraviroc)
Fixed-dose Combinations
AtriplaAtripla (efavirenz + emtricitabine + tenofovir)
CombivirCombivir (zidovudine + lamivudine)
TrizivirTrizivir (abacavir + zidovudine + lamivudine)
TruvadaTruvada (tenofovir + emtricitabine)